Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
8.07
-0.33 (-3.93%)
At close: Mar 28, 2025, 4:00 PM
7.77
-0.30 (-3.71%)
Pre-market: Mar 31, 2025, 8:53 AM EDT

Company Description

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments.

The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema.

It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases.

The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis.

Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Intellia Therapeutics, Inc.
Intellia Therapeutics logo
Country United States
Founded 2014
IPO Date May 6, 2016
Industry Biotechnology
Sector Healthcare
Employees 403
CEO John Leonard

Contact Details

Address:
40 Erie Street, Suite 130
Cambridge, Massachusetts 02139
United States
Phone 857 285 6200
Website intelliatx.com

Stock Details

Ticker Symbol NTLA
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001652130
CUSIP Number 45826J105
ISIN Number US45826J1051
Employer ID 36-4785571
SIC Code 2835

Key Executives

Name Position
Dr. Laura Sepp-Lorenzino Ph.D. Special Advisor to the Chief Executive Officer
Dr. John M. Leonard M.D. President, Chief Executive Officer and Director
Dr. David Lebwohl M.D. Executive Vice President and Chief Medical Officer
Nessan Bermingham Ph.D. Founder and Member of Scientific Advisor Board
Dr. Rachel E. Haurwitz Ph.D. Co-Founder
Dr. Andrew May Ph.D. Founder and Member of Scientific Advisor Board
Dr. Jennifer A. Doudna Ph.D. Founder and Member of Scientific Advisor Board
Dr. Derrick J. Rossi Ph.D. Founder and Member of Scientific Advisor Board
Dr. Rodolphe Barrangou M.B.A., Ph.D. Founder and Member of Scientific Advisor Board
Prof. Luciano Marraffini Ph.D. Founder and Member of Scientific Advisor Board

Latest SEC Filings

Date Type Title
Feb 28, 2025 S-8 Securities to be offered to employees in employee benefit plans
Feb 27, 2025 10-K Annual Report
Feb 27, 2025 8-K Current Report
Feb 21, 2025 8-K Current Report
Jan 10, 2025 8-K Current Report
Jan 8, 2025 SCHEDULE 13G/A Filing
Nov 18, 2024 8-K Current Report
Nov 7, 2024 10-Q Quarterly Report
Nov 7, 2024 8-K Current Report
Oct 25, 2024 8-K Current Report